PATENT CLAIM ANALYSIS

Application Number: 15997387
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "183000"]

Abstract:
Methods of treatment and pharmaceutical formulation configured to improve the cure rate of patients with solid tumors when treated with radiotherapy are provided. The methods and treatments use an inhibitor of the CXCL12/CXCR4 pathway. The inhibitors prevent the formation of new blood vessels into a tumor that is being treated with radiotherapy. The inhibitor may be continuously infused intravenously towards the end of radiotherapy and continuing thereafter.

Claim (Index 3):
The method of  claim 2 , wherein the Plerixafor is administered at a dose of at least 200 \u03bcg/kg/d.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 94.0
- Lexical Diversity: 1.39216
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13806929', '11698291', '15007002', '14356996', '14216430']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7231002592213169
- 35 USC 102 Novelty (BERT): 0.5155918764617426
- Combined Prediction Score: 0.7023494209453596
- Mean Citation Score: 222.50294
- Max Citation Score: 250.71883
- Similarity Product: 148.621046769799

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test